Group 1 - Company Gacos-B (01167.HK) announced a share buyback on October 20, 2023, spending HKD 997,000 to repurchase 127,000 shares [1]

公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年10月20日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括 ...

Core Viewpoint - The company, 加科思-B, has seen a significant stock price increase following the announcement of a strategic equity transfer agreement with 海松资本, which will enhance its focus on key oncology pipeline products [1] Group 1: Stock Performance - 加科思-B's stock rose over 7% during trading, with a current increase of 6.12%, reaching HKD 7.8, and a trading volume of HKD 23.94 million [1] Group 2: Strategic Agreement - The company signed an equity transfer agreement with 海松资本 and an industry partner, where 海松资本 will pay RMB 125 million as an initial payment and RMB 75 million as a milestone payment to acquire 80% of 加科瑞康 [1] - Following the completion of this transaction, 加科思's ownership in 加科瑞康 will decrease to 10% [1] Group 3: Strategic Focus - The transaction aligns with the company's strategy to focus on critical oncology pipeline products targeting various key cellular pathways, including KRAS, MYC, P53, and tumor immunity [1] - The proceeds from the equity transfer, after taxes and fees, will be allocated to the development, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [1]

Core Viewpoint - The stock of 加科思-B (01167) has seen a significant increase, rising over 7% during trading, attributed to a strategic equity transfer agreement with 海松资本 and an industry partner, aimed at optimizing capital allocation and focusing on key oncology pipeline products [1] Group 1: Stock Performance - 加科思-B's stock price increased by 6.12%, reaching 7.8 HKD, with a trading volume of 23.94 million HKD [1] Group 2: Strategic Agreement - 加科思 has signed an equity transfer agreement where 海松资本 will pay a total of 2 billion RMB (1.25 billion RMB upfront and 750 million RMB milestone payment) to acquire 80% of 加科瑞康 [1] - Following the completion of this transaction, 加科思's ownership in 加科瑞康 will decrease to 10% [1] Group 3: Strategic Focus - The transaction aligns with the company's strategy to focus on critical oncology pipeline products, including KRAS, MYC, P53, and tumor immunology [1] - The proceeds from the equity transfer will be used for the research, production, and commercialization of the Pan-KRAS inhibitor and other innovative oncology projects [1]

Summary of Key Points Core Viewpoint - On October 17, 42 Hong Kong-listed companies conducted share buybacks, totaling 46.36 million shares and an aggregate amount of HKD 621 million [1][2]. Company-Specific Summaries - **Xiaomi Group-W**: - Repurchased 10.70 million shares for HKD 494 million, with a highest price of HKD 46.760 and a lowest price of HKD 45.900. The total buyback amount for the year reached HKD 1.537 billion [1][2]. - **Sihuan Pharmaceutical**: - Repurchased 15 million shares for HKD 21.76 million, with a highest price of HKD 1.470 and a lowest price of HKD 1.430. The total buyback amount for the year reached HKD 143.32 million [1][2]. - **Mengniu Dairy**: - Repurchased 1.20 million shares for HKD 16.97 million, with a highest price of HKD 14.250 and a lowest price of HKD 14.070. The total buyback amount for the year reached HKD 433.54 million [1][2]. - **AAC Technologies**: - Repurchased 300,000 shares for HKD 11.60 million, with a highest price of HKD 38.800 and a lowest price of HKD 38.480. The total buyback amount for the year reached HKD 84.64 million [1][2]. - **Vitasoy International**: - Repurchased 1.02 million shares for HKD 8.20 million, with a highest price of HKD 8.040 and a lowest price of HKD 8.020. The total buyback amount for the year reached HKD 27.54 million [1][2]. Overall Market Activity - The highest buyback amount on October 17 was from Xiaomi Group-W at HKD 494 million, followed by Sihuan Pharmaceutical at HKD 21.76 million. Other notable companies included Mengniu Dairy and AAC Technologies [1][2]. - In terms of share quantity, Sihuan Pharmaceutical led with 15 million shares repurchased, followed by Xiaomi Group-W with 10.70 million shares and Anton Oilfield Services with 4.49 million shares [1][2].

Core Viewpoint - Multiple companies in China conducted share buybacks on October 17, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1][2] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 10.70 million shares for a total of 494 million yuan, with a year-to-date total of 27.30 million shares, representing 0.110% of its total share capital [2] - Four Seasons Pharmaceutical (00460) repurchased 15 million shares for 21.76 million yuan, with a year-to-date total of 59.60 million shares, representing 0.647% of its total share capital [2] - Mengniu Dairy (02319) repurchased 1.20 million shares for 16.97 million yuan, with a year-to-date total of 18.52 million shares, representing 0.473% of its total share capital [2] Group 2: Other Notable Buybacks - VITASOY International (00345) repurchased 1.02 million shares for 8.20 million yuan, with a year-to-date total of 566.60 million shares, representing 0.540% of its total share capital [2] - Zhongtong Express-W (02057) repurchased 445,000 shares for 8.41 million yuan, with a year-to-date total of 5.07 million shares, representing 0.630% of its total share capital [2] - Huazhong Media (00685) repurchased 500,000 shares for 50,000 yuan, with a year-to-date total of 225.60 million shares, representing 0.139% of its total share capital [2]

Summary of Key Points Core Viewpoint - 加科思-B (01167.HK) announced a share buyback of 135,000 shares at a cost of HKD 990,000 on October 17 [1] Group 1 - The company executed a buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 990,000, reflecting the company's financial strategy [1] - The number of shares repurchased was 135,000, which may influence the stock's liquidity and market perception [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年10月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括 ...

Core Viewpoint - The article discusses the strategic moves of 加科思 (Gakosi) in the biopharmaceutical sector, particularly focusing on its divestment of a cardiovascular project to 海松资本 (Haisong Capital) and the subsequent reinvestment into its core oncology pipeline, especially the development of a Pan-KRAS inhibitor [2][4][9]. Group 1: Transaction Details - 加科思 announced a capital increase and equity transfer involving a cardiovascular treatment project, previously held by its subsidiary 加科瑞康 (Gakosi Ruikang), to 海松资本, which will acquire 80% of the subsidiary [2][4]. - The transaction includes an initial payment of 125 million yuan and a milestone payment of 75 million yuan, totaling 200 million yuan, which will be used for the development, production, and commercialization of its core oncology pipeline [2][3][4]. Group 2: Strategic Focus - Following the divestment of non-core assets, 加科思 aims to concentrate on the oncology field, enhancing its cash flow and retaining a 10% stake in 加科瑞康 for potential future benefits [4][6]. - The company has a strong focus on the Pan-KRAS inhibitor, which is a significant target in its pipeline, as KRAS mutations are linked to a high percentage of cancer cases [11][13]. Group 3: Clinical Development Plans - 海松资本 plans to leverage China's clinical advantages to expedite the development of the pipeline, with intentions to submit an IND application in the first half of next year, aiming to enter clinical trials [7][9]. - The Pan-KRAS inhibitor is currently undergoing I/IIa phase clinical trials in China and the U.S., with results expected to be announced in mid-2026 [14][15]. Group 4: Market Context - The article highlights the competitive landscape for Pan-KRAS inhibitors, noting that other companies like Pfizer and BeiGene are also advancing similar projects in clinical stages [15]. - 加科思's leadership emphasizes the potential of iADC (immune-stimulating antibody-drug conjugates) as a high-risk but high-reward area, indicating a broader strategy in innovative cancer therapies [15].

Core Viewpoint - The announcement by Gakos-B (01167.HK) regarding a capital increase and equity transfer transaction highlights a strategic shift towards focusing on its core oncology business while divesting non-core assets, specifically a cardiovascular treatment project [2][3]. Group 1: Transaction Details - Gakos-B has entered into a transaction where Haisheng Capital will acquire 80% of the equity in Gakos-Rikang, a wholly-owned subsidiary of Gakos-B, for a total consideration of 200 million yuan, which will be used to support the development, production, and commercialization of its core oncology pipeline [2][4]. - The payment structure includes an initial payment of 125 million yuan and a milestone payment of 75 million yuan [2]. Group 2: Strategic Focus - Following the divestment, Gakos-B aims to concentrate its resources on the oncology sector, which is deemed more suitable for the company's current development stage [3][4]. - The company retains a 10% stake in Gakos-Rikang, allowing it to benefit from potential future gains [2]. Group 3: Investment and Development Plans - Haisheng Capital, a diversified investment firm with over 25 billion yuan under management, sees significant potential in the Chinese innovative drug sector and plans to leverage clinical advantages in China to expedite the development of the cardiovascular pipeline [4][5]. - Gakos-B's 200 million yuan from the equity transfer is expected to cover a substantial portion of its research and development expenses for the next six months, with a focus on the Pan-KRAS inhibitor and other innovative oncology projects [5][9]. Group 4: Research and Development Focus - The Pan-KRAS inhibitor is a priority for Gakos-B, which aims to develop a leading global product in this area, as KRAS mutations are linked to a significant percentage of cancer cases [6][8]. - Gakos-B is currently conducting I/IIa phase clinical trials for its Pan-KRAS inhibitor in both China and the United States, with results expected in mid-2026 [9].